Rising Payor Influence Means Successful Drug Launches are Rarer
Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.
By Sarah Rickwood
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.